FOURKITES
29.9.2021 11:14:07 CEST | Business Wire | Press release
FourKites® , the world’s leading real-time supply chain visibility platform , today introduced its Order Intelligence Hub, a new single-pane-of-glass view of the entire lifecycle of every order. By integrating order data, load information across modes, yard shipments, inventory visibility and other critical third-party systems, such as warehouse management systems and order management systems, shippers and their supply chain partners now have a powerful new tool to eliminate inefficiencies, manage exceptions, reduce expenses and increase customer satisfaction at every step of an order’s journey. With the goal of breaking down silos across systems, this solution was developed in close collaboration with major consumer packaged goods (CPG) customers and driven by insights from some of the largest companies in the Consumer Brand Association, which champions more than 1,700 leading CPG brands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005410/en/
As part of the recently announced Supply Chain Health and Performance Task Force , the mission of which is to increase visibility and ease supply chain pressures across the CPG industry, FourKites worked closely with Consumer Brands and 15 of its members to identify common pain points and create a solution that would address those challenges by breaking down silos between teams and systems, and leveraging the scale of the FourKites network to provide unprecedented visibility into the CPG supply chain ecosystem . Through shared dashboards, participating members can take advantage of a real-time view of facilities, lanes and interchanges causing the most inefficiencies for CPG companies. With Order Intelligence Hub, users can drill down into the line-item level impacts of bottlenecks, and can then collaborate across teams to resolve those inefficiencies.
“Collaboration is essential for building modern, resilient supply chains,” said Tom Madrecki, vice president of supply chain and logistics at Consumer Brands. “The Supply Chain Health and Performance Task Force — in partnership with FourKites — is bringing more visibility, agility and data sharing to our supply chain, allowing the CPG industry to better navigate future challenges and ensure the reliable delivery of essential goods.”
By eliminating silos and integrating disparate systems, FourKites’ Order Intelligence Hub enables collaboration and insight throughout the lifecycle of every order. Teams can much more effectively manage exceptions by identifying issues and their root causes in real time, anywhere. Customisable, persona-based dashboards provide every stakeholder group — from supply planning through to customer service and facilities management — with the data and metrics that matter most to them. And the entire community benefits from FourKites‘ market-leading network data set, collected via working with more of the world’s leading brands than any other visibility provider, including 18 of the top-20 F&B brands and nine of the top-10 CPG companies.
“The Order Intelligence Hub is a big milestone as we execute on our vision to connect the physical and digital worlds of warehouses, stores and transportation with real-time data and machine learning,” said Mathew Elenjickal, founder and CEO of FourKites. “Collaborating with our customers and other industry leaders, like Consumer Brands, in product development has enabled us to bring to market some of the most innovative solutions that address the industry’s most critical pain points.”
With the Order Intelligence Hub, FourKites builds on its long history of industry-first innovations , including multimodal purchase order tracking , which provides line-item level shipment detail using PO numbers, and Dynamic Yard , which gives enterprises the ability to proactively manage all of their facilities based on real-time, in-yard freight data and analytics. FourKites and its largest customers, which ship some of the world’s leading brands to locations around the world, have integrated previously siloed systems across customer service, transportation planning, supply/demand planning and warehouse management to enable internal stakeholder communication and insights throughout the lifecycle of every order.
About FourKites
FourKites® is a leading global supply chain visibility platform, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 620 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005410/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
